Fundraising Fox

FEMSelect

Founded 2012 · 14 employees on LinkedIn · 8 known investors

FemSelect develops EnPlace, an FDA-cleared, minimally invasive same-day treatment for Pelvic Organ Prolapse in women. The device addresses dropping of the uterus and cervix by supporting the pelvic floor, offering an alternative to pessaries, physical therapy, and Kegels.

Digital HealthFemTechMedical Devices

Founders & leadership

SS
Sasha SchrodeinChief Executive Officer

Investors · 8

Robin Hood VenturesPhiladelphia · $250K – $1Mvia Pitou Devgon · inferred
TransPacific Venture PartnersTaipei City · $500K – $3M
TriventuresHerzliya · $1M – $3M
New Age Venturesreported · 2 sourcesNew York

Also in the syndicate · 4

Avea VenturesNordwand CapitalRAD BiomedTerra Verde Comp

Funding

SEC filings, press & company announcements

$9M disclosed across 1 of 4 rounds · 2022–2026

Source: company announcements and press reports — follow each round's link for the claim.

Competitors · 1

by search overlap
Boston Scientific24 shared keywordsBoston Scientific supports external researcher-initiated studies through its Investigator Sponsored Research program, which funds independent investigations addressing disease understanding and treatment gaps of interest to the medical community.

Companies competing with FEMSelect for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

FEMSelect Announces Close of Oversubscribed Series B Equity Financing to Drive Commercial Growth, Leadership Transformation, and Global Expansion - FEMSelectfemselect.com · Feb 2026FEMSelect Closes Series B to Advance Pelvic Organ Prolapse Technology | Femtech Insiderfemtechinsider.com · May 2025Prolapse device makers FEMSelect secures new funding and announces move to USfuturefemhealth.com · May 2025Femtech in 2022: A Year in Headlines | Femtech Insiderfemtechinsider.com · Dec 2022Medtech Company FEMSelect Raises a $9M Series B for Its Minimally Invasive Approach to Pelvic Floor Ligament Fixation | Femtech Insiderfemtechinsider.com · Oct 2022FEMSelect Raises US$9M in Series B Financingfinsmes.com · Oct 2022

Frequently asked questions

What does FEMSelect do?
FemSelect develops EnPlace, an FDA-cleared, minimally invasive same-day treatment for Pelvic Organ Prolapse in women. The device addresses dropping of the uterus and cervix by supporting the pelvic floor, offering an alternative to pessaries, physical therapy, and Kegels.
Who are FEMSelect's investors?
FEMSelect's investors include Robin Hood Ventures, TransPacific Venture Partners, Triventures, New Age Ventures.
How much funding has FEMSelect raised?
FEMSelect has disclosed $9M raised across 1 of its 4 known rounds.